PPARγ and AKt gene modulation following pregabalin and duloxetine combination for painful diabetic polyneuropathy

Diabetic peripheral neuropathy (DPN) induces chronic neuropathic pain in diabetic patients. Current treatments like pregabalin and duloxetine offer limited efficacy. This study evaluates combining pregabalin and duloxetine versus pregabalin alone for DPN pain relief, and explores gene modulation ( a...

Full description

Saved in:

Bibliographic Details
Published in:	Pain management Vol. 14; no. 5-6; p. 273
Main Authors:	Saxena, Ashok K, Thanikkal, Nimisha, Chilkoti, Geetanjali T, Gondode, Prakash G, Sharma, Tusha, Banerjee, Basu D
Format:	Journal Article
Language:	English
Published:	England 02-06-2024
Subjects:	Adult Aged Analgesics - administration & dosage Analgesics - pharmacology Diabetic Neuropathies - drug therapy Drug Therapy, Combination Duloxetine Hydrochloride - administration & dosage Female Humans Male Middle Aged Neuralgia - drug therapy Neuralgia - genetics Pain Measurement PPAR gamma - genetics Pregabalin - administration & dosage Pregabalin - pharmacology Proto-Oncogene Proteins c-akt - genetics Proto-Oncogene Proteins c-akt - metabolism Quality of Life Diabetic peripheral neuropathy (DPN) PPARγ and Akt genes neuropathic pain relief pregabalin–duloxetine combination therapy gene modulation
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Diabetic peripheral neuropathy (DPN) induces chronic neuropathic pain in diabetic patients. Current treatments like pregabalin and duloxetine offer limited efficacy. This study evaluates combining pregabalin and duloxetine versus pregabalin alone for DPN pain relief, and explores gene modulation ( and ) to understand neuropathic pain's molecular basis. Diabetic patients with DPN were randomized into groups receiving combination therapy or pregabalin alone for 4 weeks. Pain intensity, gene expression and quality of life were assessed. Combination therapy significantly reduced pain, improved quality of life and upregulated and genes compared with monotherapy. Pregabalin and duloxetine combination therapy in DPN led to mRNA upregulation and negative correlation of gene expression with pain scores. This combination therapy effectively reduced pain and improved quality of life. CTRI/2021/02/031068.
ISSN:	1758-1877
DOI:	10.1080/17581869.2024.2370758